According to our LPI (LP Information) latest study, the global Anthrax Vaccines market size was valued at US$ 640.8 million in 2023. With growing demand in downstream market, the Anthrax Vaccines is forecast to a readjusted size of US$ 1089.9 million by 2030 with a CAGR of 7.9% during review period.
The research report highlights the growth potential of the global Anthrax Vaccines market. Anthrax Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anthrax Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anthrax Vaccines market.
Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.
North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.
In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.
Key Features:
The report on Anthrax Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Anthrax Vaccines market. It may include historical data, market Segmentation by Type (e.g., Live Vaccines, Cell free PA Vaccines), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Anthrax Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Anthrax Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Anthrax Vaccines industry. This include advancements in Anthrax Vaccines technology, Anthrax Vaccines new entrants, Anthrax Vaccines new investment, and other innovations that are shaping the future of Anthrax Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Anthrax Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for Anthrax Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Anthrax Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anthrax Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Anthrax Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Anthrax Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anthrax Vaccines market.
Market Segmentation:
Anthrax Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Live Vaccines
- Cell free PA Vaccines
Segmentation by application
- Human Use
- Animal Use
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Emergent BioSolutions
- Merial
- Merck
- Zoetis
- Bayer Sanidad Animal
- Colorado Serum
- PharmAthene
- Tiankang
- Biogénesis-Bago
- CAVAC
- Rosenbusch
- Agrovet
- Vecol
- CVCRI
- IVPM
- Prondil
- CDV
- Indian Immunologicals
- Botswana Vaccine Institute
- Ceva Santé Animale
- Intervac
- JOVAC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Anthrax Vaccines market?
What factors are driving Anthrax Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anthrax Vaccines market opportunities vary by end market size?
How does Anthrax Vaccines break out type, application?
Global Anthrax Vaccines Market Growth 2024-2030
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anthrax Vaccines Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anthrax Vaccines by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anthrax Vaccines by Country/Region, 2019, 2023 & 2030
2.2 Anthrax Vaccines Segment by Type
2.2.1 Live Vaccines
2.2.2 Cell free PA Vaccines
2.3 Anthrax Vaccines Sales by Type
2.3.1 Global Anthrax Vaccines Sales Market Share by Type (2019-2024)
2.3.2 Global Anthrax Vaccines Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anthrax Vaccines Sale Price by Type (2019-2024)
2.4 Anthrax Vaccines Segment by Application
2.4.1 Human Use
2.4.2 Animal Use
2.5 Anthrax Vaccines Sales by Application
2.5.1 Global Anthrax Vaccines Sale Market Share by Application (2019-2024)
2.5.2 Global Anthrax Vaccines Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anthrax Vaccines Sale Price by Application (2019-2024)
3 Global Anthrax Vaccines by Company
3.1 Global Anthrax Vaccines Breakdown Data by Company
3.1.1 Global Anthrax Vaccines Annual Sales by Company (2019-2024)
3.1.2 Global Anthrax Vaccines Sales Market Share by Company (2019-2024)
3.2 Global Anthrax Vaccines Annual Revenue by Company (2019-2024)
3.2.1 Global Anthrax Vaccines Revenue by Company (2019-2024)
3.2.2 Global Anthrax Vaccines Revenue Market Share by Company (2019-2024)
3.3 Global Anthrax Vaccines Sale Price by Company
3.4 Key Manufacturers Anthrax Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anthrax Vaccines Product Location Distribution
3.4.2 Players Anthrax Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Anthrax Vaccines by Geographic Region
4.1 World Historic Anthrax Vaccines Market Size by Geographic Region (2019-2024)
4.1.1 Global Anthrax Vaccines Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anthrax Vaccines Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anthrax Vaccines Market Size by Country/Region (2019-2024)
4.2.1 Global Anthrax Vaccines Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anthrax Vaccines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anthrax Vaccines Sales Growth
4.4 APAC Anthrax Vaccines Sales Growth
4.5 Europe Anthrax Vaccines Sales Growth
4.6 Middle East & Africa Anthrax Vaccines Sales Growth
5 Americas
5.1 Americas Anthrax Vaccines Sales by Country
5.1.1 Americas Anthrax Vaccines Sales by Country (2019-2024)
5.1.2 Americas Anthrax Vaccines Revenue by Country (2019-2024)
5.2 Americas Anthrax Vaccines Sales by Type
5.3 Americas Anthrax Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anthrax Vaccines Sales by Region
6.1.1 APAC Anthrax Vaccines Sales by Region (2019-2024)
6.1.2 APAC Anthrax Vaccines Revenue by Region (2019-2024)
6.2 APAC Anthrax Vaccines Sales by Type
6.3 APAC Anthrax Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Anthrax Vaccines by Country
7.1.1 Europe Anthrax Vaccines Sales by Country (2019-2024)
7.1.2 Europe Anthrax Vaccines Revenue by Country (2019-2024)
7.2 Europe Anthrax Vaccines Sales by Type
7.3 Europe Anthrax Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anthrax Vaccines by Country
8.1.1 Middle East & Africa Anthrax Vaccines Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anthrax Vaccines Revenue by Country (2019-2024)
8.2 Middle East & Africa Anthrax Vaccines Sales by Type
8.3 Middle East & Africa Anthrax Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anthrax Vaccines
10.3 Manufacturing Process Analysis of Anthrax Vaccines
10.4 Industry Chain Structure of Anthrax Vaccines
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anthrax Vaccines Distributors
11.3 Anthrax Vaccines Customer
12 World Forecast Review for Anthrax Vaccines by Geographic Region
12.1 Global Anthrax Vaccines Market Size Forecast by Region
12.1.1 Global Anthrax Vaccines Forecast by Region (2025-2030)
12.1.2 Global Anthrax Vaccines Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anthrax Vaccines Forecast by Type
12.7 Global Anthrax Vaccines Forecast by Application
13 Key Players Analysis
13.1 Emergent BioSolutions
13.1.1 Emergent BioSolutions Company Information
13.1.2 Emergent BioSolutions Anthrax Vaccines Product Portfolios and Specifications
13.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Emergent BioSolutions Main Business Overview
13.1.5 Emergent BioSolutions Latest Developments
13.2 Merial
13.2.1 Merial Company Information
13.2.2 Merial Anthrax Vaccines Product Portfolios and Specifications
13.2.3 Merial Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merial Main Business Overview
13.2.5 Merial Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Anthrax Vaccines Product Portfolios and Specifications
13.3.3 Merck Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Zoetis
13.4.1 Zoetis Company Information
13.4.2 Zoetis Anthrax Vaccines Product Portfolios and Specifications
13.4.3 Zoetis Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Zoetis Main Business Overview
13.4.5 Zoetis Latest Developments
13.5 Bayer Sanidad Animal
13.5.1 Bayer Sanidad Animal Company Information
13.5.2 Bayer Sanidad Animal Anthrax Vaccines Product Portfolios and Specifications
13.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Bayer Sanidad Animal Main Business Overview
13.5.5 Bayer Sanidad Animal Latest Developments
13.6 Colorado Serum
13.6.1 Colorado Serum Company Information
13.6.2 Colorado Serum Anthrax Vaccines Product Portfolios and Specifications
13.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Colorado Serum Main Business Overview
13.6.5 Colorado Serum Latest Developments
13.7 PharmAthene
13.7.1 PharmAthene Company Information
13.7.2 PharmAthene Anthrax Vaccines Product Portfolios and Specifications
13.7.3 PharmAthene Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 PharmAthene Main Business Overview
13.7.5 PharmAthene Latest Developments
13.8 Tiankang
13.8.1 Tiankang Company Information
13.8.2 Tiankang Anthrax Vaccines Product Portfolios and Specifications
13.8.3 Tiankang Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Tiankang Main Business Overview
13.8.5 Tiankang Latest Developments
13.9 Biogénesis-Bago
13.9.1 Biogénesis-Bago Company Information
13.9.2 Biogénesis-Bago Anthrax Vaccines Product Portfolios and Specifications
13.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Biogénesis-Bago Main Business Overview
13.9.5 Biogénesis-Bago Latest Developments
13.10 CAVAC
13.10.1 CAVAC Company Information
13.10.2 CAVAC Anthrax Vaccines Product Portfolios and Specifications
13.10.3 CAVAC Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 CAVAC Main Business Overview
13.10.5 CAVAC Latest Developments
13.11 Rosenbusch
13.11.1 Rosenbusch Company Information
13.11.2 Rosenbusch Anthrax Vaccines Product Portfolios and Specifications
13.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Rosenbusch Main Business Overview
13.11.5 Rosenbusch Latest Developments
13.12 Agrovet
13.12.1 Agrovet Company Information
13.12.2 Agrovet Anthrax Vaccines Product Portfolios and Specifications
13.12.3 Agrovet Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Agrovet Main Business Overview
13.12.5 Agrovet Latest Developments
13.13 Vecol
13.13.1 Vecol Company Information
13.13.2 Vecol Anthrax Vaccines Product Portfolios and Specifications
13.13.3 Vecol Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Vecol Main Business Overview
13.13.5 Vecol Latest Developments
13.14 CVCRI
13.14.1 CVCRI Company Information
13.14.2 CVCRI Anthrax Vaccines Product Portfolios and Specifications
13.14.3 CVCRI Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 CVCRI Main Business Overview
13.14.5 CVCRI Latest Developments
13.15 IVPM
13.15.1 IVPM Company Information
13.15.2 IVPM Anthrax Vaccines Product Portfolios and Specifications
13.15.3 IVPM Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 IVPM Main Business Overview
13.15.5 IVPM Latest Developments
13.16 Prondil
13.16.1 Prondil Company Information
13.16.2 Prondil Anthrax Vaccines Product Portfolios and Specifications
13.16.3 Prondil Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Prondil Main Business Overview
13.16.5 Prondil Latest Developments
13.17 CDV
13.17.1 CDV Company Information
13.17.2 CDV Anthrax Vaccines Product Portfolios and Specifications
13.17.3 CDV Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 CDV Main Business Overview
13.17.5 CDV Latest Developments
13.18 Indian Immunologicals
13.18.1 Indian Immunologicals Company Information
13.18.2 Indian Immunologicals Anthrax Vaccines Product Portfolios and Specifications
13.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Indian Immunologicals Main Business Overview
13.18.5 Indian Immunologicals Latest Developments
13.19 Botswana Vaccine Institute
13.19.1 Botswana Vaccine Institute Company Information
13.19.2 Botswana Vaccine Institute Anthrax Vaccines Product Portfolios and Specifications
13.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Botswana Vaccine Institute Main Business Overview
13.19.5 Botswana Vaccine Institute Latest Developments
13.20 Ceva Santé Animale
13.20.1 Ceva Santé Animale Company Information
13.20.2 Ceva Santé Animale Anthrax Vaccines Product Portfolios and Specifications
13.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Ceva Santé Animale Main Business Overview
13.20.5 Ceva Santé Animale Latest Developments
13.21 Intervac
13.21.1 Intervac Company Information
13.21.2 Intervac Anthrax Vaccines Product Portfolios and Specifications
13.21.3 Intervac Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Intervac Main Business Overview
13.21.5 Intervac Latest Developments
13.22 JOVAC
13.22.1 JOVAC Company Information
13.22.2 JOVAC Anthrax Vaccines Product Portfolios and Specifications
13.22.3 JOVAC Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 JOVAC Main Business Overview
13.22.5 JOVAC Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Anthrax Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anthrax Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Live Vaccines
Table 4. Major Players of Cell free PA Vaccines
Table 5. Global Anthrax Vaccines Sales by Type (2019-2024) & (M Doses)
Table 6. Global Anthrax Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Anthrax Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Anthrax Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Anthrax Vaccines Sale Price by Type (2019-2024) & (USD/Dose)
Table 10. Global Anthrax Vaccines Sales by Application (2019-2024) & (M Doses)
Table 11. Global Anthrax Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Anthrax Vaccines Revenue by Application (2019-2024)
Table 13. Global Anthrax Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Anthrax Vaccines Sale Price by Application (2019-2024) & (USD/Dose)
Table 15. Global Anthrax Vaccines Sales by Company (2019-2024) & (M Doses)
Table 16. Global Anthrax Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Anthrax Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Anthrax Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Anthrax Vaccines Sale Price by Company (2019-2024) & (USD/Dose)
Table 20. Key Manufacturers Anthrax Vaccines Producing Area Distribution and Sales Area
Table 21. Players Anthrax Vaccines Products Offered
Table 22. Anthrax Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Anthrax Vaccines Sales by Geographic Region (2019-2024) & (M Doses)
Table 26. Global Anthrax Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Anthrax Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Anthrax Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Anthrax Vaccines Sales by Country/Region (2019-2024) & (M Doses)
Table 30. Global Anthrax Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Anthrax Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Anthrax Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Anthrax Vaccines Sales by Country (2019-2024) & (M Doses)
Table 34. Americas Anthrax Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Anthrax Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Anthrax Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Anthrax Vaccines Sales by Type (2019-2024) & (M Doses)
Table 38. Americas Anthrax Vaccines Sales by Application (2019-2024) & (M Doses)
Table 39. APAC Anthrax Vaccines Sales by Region (2019-2024) & (M Doses)
Table 40. APAC Anthrax Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Anthrax Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Anthrax Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Anthrax Vaccines Sales by Type (2019-2024) & (M Doses)
Table 44. APAC Anthrax Vaccines Sales by Application (2019-2024) & (M Doses)
Table 45. Europe Anthrax Vaccines Sales by Country (2019-2024) & (M Doses)
Table 46. Europe Anthrax Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Anthrax Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Anthrax Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Anthrax Vaccines Sales by Type (2019-2024) & (M Doses)
Table 50. Europe Anthrax Vaccines Sales by Application (2019-2024) & (M Doses)
Table 51. Middle East & Africa Anthrax Vaccines Sales by Country (2019-2024) & (M Doses)
Table 52. Middle East & Africa Anthrax Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Anthrax Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Anthrax Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Anthrax Vaccines Sales by Type (2019-2024) & (M Doses)
Table 56. Middle East & Africa Anthrax Vaccines Sales by Application (2019-2024) & (M Doses)
Table 57. Key Market Drivers & Growth Opportunities of Anthrax Vaccines
Table 58. Key Market Challenges & Risks of Anthrax Vaccines
Table 59. Key Industry Trends of Anthrax Vaccines
Table 60. Anthrax Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Anthrax Vaccines Distributors List
Table 63. Anthrax Vaccines Customer List
Table 64. Global Anthrax Vaccines Sales Forecast by Region (2025-2030) & (M Doses)
Table 65. Global Anthrax Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Anthrax Vaccines Sales Forecast by Country (2025-2030) & (M Doses)
Table 67. Americas Anthrax Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Anthrax Vaccines Sales Forecast by Region (2025-2030) & (M Doses)
Table 69. APAC Anthrax Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Anthrax Vaccines Sales Forecast by Country (2025-2030) & (M Doses)
Table 71. Europe Anthrax Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Anthrax Vaccines Sales Forecast by Country (2025-2030) & (M Doses)
Table 73. Middle East & Africa Anthrax Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Anthrax Vaccines Sales Forecast by Type (2025-2030) & (M Doses)
Table 75. Global Anthrax Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Anthrax Vaccines Sales Forecast by Application (2025-2030) & (M Doses)
Table 77. Global Anthrax Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Emergent BioSolutions Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. Emergent BioSolutions Anthrax Vaccines Product Portfolios and Specifications
Table 80. Emergent BioSolutions Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 81. Emergent BioSolutions Main Business
Table 82. Emergent BioSolutions Latest Developments
Table 83. Merial Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Merial Anthrax Vaccines Product Portfolios and Specifications
Table 85. Merial Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 86. Merial Main Business
Table 87. Merial Latest Developments
Table 88. Merck Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Merck Anthrax Vaccines Product Portfolios and Specifications
Table 90. Merck Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 91. Merck Main Business
Table 92. Merck Latest Developments
Table 93. Zoetis Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Zoetis Anthrax Vaccines Product Portfolios and Specifications
Table 95. Zoetis Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 96. Zoetis Main Business
Table 97. Zoetis Latest Developments
Table 98. Bayer Sanidad Animal Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Bayer Sanidad Animal Anthrax Vaccines Product Portfolios and Specifications
Table 100. Bayer Sanidad Animal Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 101. Bayer Sanidad Animal Main Business
Table 102. Bayer Sanidad Animal Latest Developments
Table 103. Colorado Serum Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Colorado Serum Anthrax Vaccines Product Portfolios and Specifications
Table 105. Colorado Serum Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 106. Colorado Serum Main Business
Table 107. Colorado Serum Latest Developments
Table 108. PharmAthene Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. PharmAthene Anthrax Vaccines Product Portfolios and Specifications
Table 110. PharmAthene Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 111. PharmAthene Main Business
Table 112. PharmAthene Latest Developments
Table 113. Tiankang Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Tiankang Anthrax Vaccines Product Portfolios and Specifications
Table 115. Tiankang Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 116. Tiankang Main Business
Table 117. Tiankang Latest Developments
Table 118. Biogénesis-Bago Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Biogénesis-Bago Anthrax Vaccines Product Portfolios and Specifications
Table 120. Biogénesis-Bago Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 121. Biogénesis-Bago Main Business
Table 122. Biogénesis-Bago Latest Developments
Table 123. CAVAC Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. CAVAC Anthrax Vaccines Product Portfolios and Specifications
Table 125. CAVAC Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 126. CAVAC Main Business
Table 127. CAVAC Latest Developments
Table 128. Rosenbusch Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Rosenbusch Anthrax Vaccines Product Portfolios and Specifications
Table 130. Rosenbusch Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 131. Rosenbusch Main Business
Table 132. Rosenbusch Latest Developments
Table 133. Agrovet Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 134. Agrovet Anthrax Vaccines Product Portfolios and Specifications
Table 135. Agrovet Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 136. Agrovet Main Business
Table 137. Agrovet Latest Developments
Table 138. Vecol Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 139. Vecol Anthrax Vaccines Product Portfolios and Specifications
Table 140. Vecol Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 141. Vecol Main Business
Table 142. Vecol Latest Developments
Table 143. CVCRI Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 144. CVCRI Anthrax Vaccines Product Portfolios and Specifications
Table 145. CVCRI Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 146. CVCRI Main Business
Table 147. CVCRI Latest Developments
Table 148. IVPM Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 149. IVPM Anthrax Vaccines Product Portfolios and Specifications
Table 150. IVPM Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 151. IVPM Main Business
Table 152. IVPM Latest Developments
Table 153. Prondil Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 154. Prondil Anthrax Vaccines Product Portfolios and Specifications
Table 155. Prondil Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 156. Prondil Main Business
Table 157. Prondil Latest Developments
Table 158. CDV Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 159. CDV Anthrax Vaccines Product Portfolios and Specifications
Table 160. CDV Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 161. CDV Main Business
Table 162. CDV Latest Developments
Table 163. Indian Immunologicals Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 164. Indian Immunologicals Anthrax Vaccines Product Portfolios and Specifications
Table 165. Indian Immunologicals Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 166. Indian Immunologicals Main Business
Table 167. Indian Immunologicals Latest Developments
Table 168. Botswana Vaccine Institute Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 169. Botswana Vaccine Institute Anthrax Vaccines Product Portfolios and Specifications
Table 170. Botswana Vaccine Institute Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 171. Botswana Vaccine Institute Main Business
Table 172. Botswana Vaccine Institute Latest Developments
Table 173. Ceva Santé Animale Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 174. Ceva Santé Animale Anthrax Vaccines Product Portfolios and Specifications
Table 175. Ceva Santé Animale Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 176. Ceva Santé Animale Main Business
Table 177. Ceva Santé Animale Latest Developments
Table 178. Intervac Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 179. Intervac Anthrax Vaccines Product Portfolios and Specifications
Table 180. Intervac Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 181. Intervac Main Business
Table 182. Intervac Latest Developments
Table 183. JOVAC Basic Information, Anthrax Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 184. JOVAC Anthrax Vaccines Product Portfolios and Specifications
Table 185. JOVAC Anthrax Vaccines Sales (M Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 186. JOVAC Main Business
Table 187. JOVAC Latest Developments
List of Figures
Figure 1. Picture of Anthrax Vaccines
Figure 2. Anthrax Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anthrax Vaccines Sales Growth Rate 2019-2030 (M Doses)
Figure 7. Global Anthrax Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anthrax Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Live Vaccines
Figure 10. Product Picture of Cell free PA Vaccines
Figure 11. Global Anthrax Vaccines Sales Market Share by Type in 2023
Figure 12. Global Anthrax Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Anthrax Vaccines Consumed in Human Use
Figure 14. Global Anthrax Vaccines Market: Human Use (2019-2024) & (M Doses)
Figure 15. Anthrax Vaccines Consumed in Animal Use
Figure 16. Global Anthrax Vaccines Market: Animal Use (2019-2024) & (M Doses)
Figure 17. Global Anthrax Vaccines Sales Market Share by Application (2023)
Figure 18. Global Anthrax Vaccines Revenue Market Share by Application in 2023
Figure 19. Anthrax Vaccines Sales Market by Company in 2023 (M Doses)
Figure 20. Global Anthrax Vaccines Sales Market Share by Company in 2023
Figure 21. Anthrax Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Anthrax Vaccines Revenue Market Share by Company in 2023
Figure 23. Global Anthrax Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Anthrax Vaccines Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Anthrax Vaccines Sales 2019-2024 (M Doses)
Figure 26. Americas Anthrax Vaccines Revenue 2019-2024 ($ Millions)
Figure 27. APAC Anthrax Vaccines Sales 2019-2024 (M Doses)
Figure 28. APAC Anthrax Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. Europe Anthrax Vaccines Sales 2019-2024 (M Doses)
Figure 30. Europe Anthrax Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Anthrax Vaccines Sales 2019-2024 (M Doses)
Figure 32. Middle East & Africa Anthrax Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Americas Anthrax Vaccines Sales Market Share by Country in 2023
Figure 34. Americas Anthrax Vaccines Revenue Market Share by Country in 2023
Figure 35. Americas Anthrax Vaccines Sales Market Share by Type (2019-2024)
Figure 36. Americas Anthrax Vaccines Sales Market Share by Application (2019-2024)
Figure 37. United States Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Anthrax Vaccines Sales Market Share by Region in 2023
Figure 42. APAC Anthrax Vaccines Revenue Market Share by Regions in 2023
Figure 43. APAC Anthrax Vaccines Sales Market Share by Type (2019-2024)
Figure 44. APAC Anthrax Vaccines Sales Market Share by Application (2019-2024)
Figure 45. China Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Anthrax Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Anthrax Vaccines Revenue Growth 2019-2024 ($ Millio
Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 87
The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030.
North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......
Global Esomeprazole Magnesium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 74
The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030.
North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......
Global Combination Therapy Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......
Global Axitinib Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 68
The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......
Global Lyme Disease Vaccine Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 70
The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi.
The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at......
Global Transdermal Absorption Patch Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......
Global Ketoprofen Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis
The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......
Global Methyl Salicylate Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 82
The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......
Global Diclofenac Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
